ELI LILLY & Co
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3025% above fair value
$1410.99−6.55 (-0.46%)
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly Basaglar (insulin glargine) by Year
Basaglar (insulin glargine) — Worldwide revenue YoY (%) [legacy] (%)
Eli Lilly Basaglar (insulin glargine): -7.0% in FY2024, down 3.0 pts from a year earlier. No newer figure appears in the documents we track.
Latest, FY2024
-7.0%
Period ended Dec 31, 2024
Change on a year earlier
-3.0 pts
-4.0% in FY2023
History
7 years
Since FY2018
Sources
7
Documents cited below
Where the FY2024 figure comes from
“|| Basaglar (3) | 375.4 | 301.5 | 676.9 | 728.3 | (7)”
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Basaglar (insulin glargine) — Worldwide revenue YoY (%) [legacy] (%) | Year on year | Source |
|---|---|---|---|---|
| FY2024 | Dec 31, 2024 | -7.0% | -3.0 pts | Form 10-K FY2024 (filed 2025-02-19) ↗ |
| FY2023 | Dec 31, 2023 | -4.0% | +11.0 pts | Form 10-K FY2023 (filed 2024-02-21) ↗ |
| FY2022 | Dec 31, 2022 | -15.0% | +6.0 pts | Form 10-K FY2022 (filed 2023-02-22) ↗ |
| FY2021 | Dec 31, 2021 | -21.0% | -22.0 pts | Form 10-K FY2021 (filed 2022-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 1.0% | -84.0 pts | Form 10-K FY2020 (filed 2021-02-17) ↗ |
| FY2019 | Dec 31, 2019 | 85.0% | 0.0 pts | Form 10-K FY2019 (filed 2020-02-19) ↗ |
| FY2018 | Dec 31, 2018 | 85.0% | – | Form 10-K FY2018 (filed 2019-02-19) ↗ |
Cite this data
StockData. (2026). Eli Lilly Basaglar (insulin glargine) (%), annual FY2018–FY2024 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-basaglar-yoy
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.